Terms: = Lung cancer AND HER1, YOR227W AND Treatment
71 results:
1. Zerumbone-incorporated liquid crystalline nanoparticles inhibit proliferation and migration of non-small-cell lung cancer in vitro.
Manandhar B; Paudel KR; Clarence DD; De Rubis G; Madheswaran T; Panneerselvam J; Zacconi FC; Williams KA; Pont LG; Warkiani ME; MacLoughlin R; Oliver BG; Gupta G; Singh SK; Chellappan DK; Hansbro PM; Dua K
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):343-356. PubMed ID: 37439806
[TBL] [Abstract] [Full Text] [Related]
2. Small Molecule EGFR Inhibitors as Anti-cancer Agents: Discovery, Mechanisms of Action, and Opportunities.
Zubair T; Bandyopadhyay D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768973
[TBL] [Abstract] [Full Text] [Related]
3. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
4. Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.
Liu R; Ota K; Iwama E; Yoneshima Y; Tanaka K; Inoue H; Tagawa T; Oda Y; Mori M; Nakanishi Y; Okamoto I
Lung Cancer; 2021 Aug; 158():156-161. PubMed ID: 34059353
[TBL] [Abstract] [Full Text] [Related]
5. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
6. erbB in NSCLC as a molecular target: current evidences and future directions.
Del Re M; Cucchiara F; Petrini I; Fogli S; Passaro A; Crucitta S; Attili I; De Marinis F; Chella A; Danesi R
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32820012
[TBL] [Abstract] [Full Text] [Related]
7. Dacomitinib: First Global Approval.
Shirley M
Drugs; 2018 Dec; 78(18):1947-1953. PubMed ID: 30506139
[TBL] [Abstract] [Full Text] [Related]
8. Neratinib: First Global Approval.
Deeks ED
Drugs; 2017 Oct; 77(15):1695-1704. PubMed ID: 28884417
[TBL] [Abstract] [Full Text] [Related]
9. The prospect of patritumab for treating non-small cell lung cancer.
Horinouchi H
Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
[TBL] [Abstract] [Full Text] [Related]
10. Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule.
Dobosz M; Haupt U; Scheuer W
MAbs; 2017 Jan; 9(1):140-153. PubMed ID: 27661454
[TBL] [Abstract] [Full Text] [Related]
11. TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.
Castoldi R; Schanzer J; Panke C; Jucknischke U; Neubert NJ; Croasdale R; Scheuer W; Auer J; Klein C; Niederfellner G; Kobold S; Sustmann C
Protein Eng Des Sel; 2016 Oct; 29(10):467-475. PubMed ID: 27578890
[TBL] [Abstract] [Full Text] [Related]
12. [Mechanism of action and preclinical development of afatinib].
Diz Taín P; González AL; García-Palomo A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
[TBL] [Abstract] [Full Text] [Related]
13. Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder cancer: EORTC Trial 30061.
Cerbone L; Sternberg CN; Sengeløv L; Agerbaek M; Van Herpen C; Marreaud S; Collette S; Zhang J; Daugaard G
Oncology; 2016; 90(1):21-8. PubMed ID: 26468947
[TBL] [Abstract] [Full Text] [Related]
14. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract] [Full Text] [Related]
15. The epidermal growth factor receptor (EGFR / HER-1) gatekeeper mutation T790M is present in European patients with early breast cancer.
Bemanian V; Sauer T; Touma J; Lindstedt BA; Chen Y; Ødegård HP; Vetvik KM; Bukholm IR; Geisler J
PLoS One; 2015; 10(8):e0134398. PubMed ID: 26267891
[TBL] [Abstract] [Full Text] [Related]
16. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
Giri N; Masters JC; Plotka A; Liang Y; Boutros T; Pardo P; O'Connell J; Bello C
Invest New Drugs; 2015 Aug; 33(4):931-41. PubMed ID: 26048096
[TBL] [Abstract] [Full Text] [Related]
17. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
Kris MG; Camidge DR; Giaccone G; Hida T; Li BT; O'Connell J; Taylor I; Zhang H; Arcila ME; Goldberg Z; Jänne PA
Ann Oncol; 2015 Jul; 26(7):1421-7. PubMed ID: 25899785
[TBL] [Abstract] [Full Text] [Related]
18. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.
Stachnik A; Yuen T; Iqbal J; Sgobba M; Gupta Y; Lu P; Colaianni G; Ji Y; Zhu LL; Kim SM; Li J; Liu P; Izadmehr S; Sangodkar J; Scherer T; Mujtaba S; Galsky M; Gomez J; Epstein S; Buettner C; Bian Z; Zallone A; Aggarwal AK; Haider S; New MI; Sun L; Narla G; Zaidi M
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):17995-8000. PubMed ID: 25453078
[TBL] [Abstract] [Full Text] [Related]
19. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.
Boulbes DR; Arold ST; Chauhan GB; Blachno KV; Deng N; Chang WC; Jin Q; Huang TH; Hsu JM; Brady SW; Bartholomeusz C; Ladbury JE; Stone S; Yu D; Hung MC; Esteva FJ
Mol Oncol; 2015 Mar; 9(3):586-600. PubMed ID: 25435280
[TBL] [Abstract] [Full Text] [Related]
20. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract] [Full Text] [Related]
[Next]
